irinophore c

Irinophore C is a liposomal nanoparticle formulation of the chemotherapeutic agent irinotecan, designed to improve drug delivery and reduce toxicity compared to conventional irinotecan. The nanoparticles encase irinotecan in a liposome (fat "bubble") that protects the drug until it reaches the tumor, where it is released slowly, enhancing anticancer efficacy and minimizing systemic side effects, particularly gastrointestinal toxicity[1][4]. Preclinical studies in animal models have demonstrated that Irinophore C increases survival, induces tumor regression, and improves the vascular function of tumors, which may also enhance the delivery and efficacy of other anticancer drugs[3][7]. Unlike free irinotecan, Irinophore C does not cause early- or late-onset diarrhea at equivalent doses in animal models, suggesting a significantly improved safety profile[4].

Other names

irinophore cirinophore c™liposomal irinotecan